Non-communicable disease

New Initiative Launches to Address Neglected Global Health Crisis of Alcohol Harms

Retrieved on: 
Tuesday, November 1, 2022

NEW YORK, Nov. 1, 2022 /PRNewswire/ -- Alcohol consumption is a top-ten driver of death, illness and injury, with wide-ranging social and economic harms. Many of the harms related to alcohol disproportionately affect young adults, and surveys from multiple countries suggest that the Covid-19 pandemic has further increased drinking. Today, Vital Strategies announced RESET Alcohol – a groundbreaking new $15 million initiative to reduce alcohol-related harms in hard-hit countries through policy change.

Key Points: 
  • Today, Vital Strategies announced RESET Alcohol a groundbreaking new $15 million initiative to reducealcohol-related harms in hard-hit countries through policy change.
  • Public health work on alcohol isvastly underfunded relative to the issue's burden, and the philanthropic award that founds RESET Alcohol roughly doubles existing global funding.
  • RESET Alcohol is a collaboration of six global organizations: Vital Strategies, which is leading the initiative; Movendi International ; the University of Illinois Chicago ; the Global Alcohol Policy Alliance (GAPA); the Non-Communicable Disease (NCD) Alliance ;and World Health Organization (WHO).
  • Learn more about RESET Alcohol here: https://www.vitalstrategies.org/programs/alcohol-policy/
    RESET Alcohol brings together national governments, civil society, and global leaders to advance policies from the World Health Organization's SAFER package for reducing the health, social and economic harms of alcohol.

The Medicines Patent Pool (MPP) signs licence agreement to increase access to nilotinib for the treatment of chronic myeloid leukaemia

Retrieved on: 
Thursday, October 20, 2022

GENEVA, Oct. 20, 2022 /PRNewswire/ -- On the side lines of the World Cancer Congress, the Medicines Patent Pool (MPP) today announced the signing of a voluntary licensing agreement with Novartis AG to increase access to nilotinib, a twice daily oral medication used to treat chronic myeloid leukaemia (CML), part of the World Health Organization Model List of Essential Medicines (WHO EML) for treatment in adults and children of at least one year of age.

Key Points: 
  • Advances in treatment, such as nilotinib, have contributed to a greatly improved prognosis for people diagnosed with CML.
  • Nilotinib was added to the WHO EML and EMLc respectively in 2017 and 2019 as second-line therapy for the treatment of chronic myeloid leukaemia that is resistant to imatinib.
  • MPP's work on access to NCDs is equally funded by Unitaid and the Swiss Agency for Development and Cooperation (SDC).
  • MPP invites Expressions of Interest (EoI) from potential sublicensees for sublicences to manufacture and sell nilotinib in the licensed territory:

The Medicines Patent Pool (MPP) signs licence agreement to increase access to nilotinib for the treatment of chronic myeloid leukaemia

Retrieved on: 
Thursday, October 20, 2022

GENEVA, Oct. 20, 2022 /PRNewswire/ -- On the side lines of the World Cancer Congress, the Medicines Patent Pool (MPP) today announced the signing of a voluntary licensing agreement with Novartis AG to increase access to nilotinib, a twice daily oral medication used to treat chronic myeloid leukaemia (CML), part of the World Health Organization Model List of Essential Medicines (WHO EML) for treatment in adults and children of at least one year of age.

Key Points: 
  • Advances in treatment, such as nilotinib, have contributed to a greatly improved prognosis for people diagnosed with CML.
  • Nilotinib was added to the WHO EML and EMLc respectively in 2017 and 2019 as second-line therapy for the treatment of chronic myeloid leukaemia that is resistant to imatinib.
  • MPP's work on access to NCDs is equally funded by Unitaid and the Swiss Agency for Development and Cooperation (SDC).
  • MPP invites Expressions of Interest (EoI) from potential sublicensees for sublicences to manufacture and sell nilotinib in the licensed territory:

EQS-News: How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication

Retrieved on: 
Friday, September 23, 2022

Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States.

Key Points: 
  • Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States.
  • In fact, each year, more people die from this silent killer than from breast or prostate cancer.
  • Hyperphosphatemia (elevated phosphorus levels in the blood) is a common complication of CKD affecting over 80% of dialysis patients.
  • UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury.

Heads of State Commit to Noncommunicable Disease Global Compact to Save 50 Million Lives by 2030

Retrieved on: 
Wednesday, September 21, 2022

GENEVA and NEW YORK, Sept. 21, 2022 /PRNewswire/ -- Today, Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), launched a new report calling on global leaders to take urgent action on noncommunicable diseases (NCDs), responsible for 17 million premature deaths every year.

Key Points: 
  • To accelerate action, Dr. Tedros renewed the two-year appointment of Michael R. Bloomberg as WHO Global Ambassador for Noncommunicable Diseases and Injuries.
  • This follows the launch of a Global NCD Compact earlier this year by Ghana and Norway.
  • Noncommunicable diseases like heart disease, cancer, diabetes, and lung disease now outnumber infectious disease as the top killers globally.
  • Recently, Bloomberg Philanthropies invested an additional $115 million in global public health nonprofit Resolve to Save Lives bringing its total investment to $215 million to continue preventing deaths from heart disease.

New IFPA Forum spearheads roadmap to meet the unmet needs of people living with psoriatic disease in Europe

Retrieved on: 
Monday, June 27, 2022

People with psoriatic disease experience significant unmet medical needs and carry a heavy burden mentally, physically, and economically.

Key Points: 
  • People with psoriatic disease experience significant unmet medical needs and carry a heavy burden mentally, physically, and economically.
  • The first IFPA Forum "Speaking up for psoriatic disease in Europe" will be held on 5 September 2022 in Milan, Italy.
  • The IFPA Forum will engage psoriatic associations, thought leaders, and people living with psoriatic disease in genuine collaboration.
  • Founded in 1971, IFPA is the global organization uniting all people living with psoriatic disease regardless of where they live, what type of psoriatic disease they have, or how it impacts their lives.

New IFPA Forum spearheads roadmap to meet the unmet needs of people living with psoriatic disease in Europe

Retrieved on: 
Monday, June 27, 2022

People with psoriatic disease experience significant unmet medical needs and carry a heavy burden mentally, physically, and economically.

Key Points: 
  • People with psoriatic disease experience significant unmet medical needs and carry a heavy burden mentally, physically, and economically.
  • The first IFPA Forum "Speaking up for psoriatic disease in Europe" will be held on 5 September 2022 in Milan, Italy.
  • The IFPA Forum will engage psoriatic associations, thought leaders, and people living with psoriatic disease in genuine collaboration.
  • Founded in 1971, IFPA is the global organization uniting all people living with psoriatic disease regardless of where they live, what type of psoriatic disease they have, or how it impacts their lives.

Global Patient Monitoring Market Report (2022 to 2030) - Rising Adoption of Wearable Devices is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 22, 2022

The demand for patient monitoring is increasing due to rising prevalence of infectious and chronic diseases due to changing lifestyle, coupled with growing preference towards remote monitoring.

Key Points: 
  • The demand for patient monitoring is increasing due to rising prevalence of infectious and chronic diseases due to changing lifestyle, coupled with growing preference towards remote monitoring.
  • All these factors are expected to support the growth of the global patient monitoring market
    However, higher cost of patient monitoring devices is expected to restraint the growth of market during the forecast period.
  • On the contrary, growing demand for patient monitoring devices in non-hospital settings and increasing investments in healthcare IT are expected to create ample growth opportunities for the patient monitoring market in the upcoming years.
  • However, Asia Pacific is expected to show a swift rise in the market due to rise in adoption of remote patient monitoring devices.

Insights on the Renal Biomarkers Global Market to 2027 - by Biomarker Type, Diagnostic Technique, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Friday, June 17, 2022

As they also aid in predicting disease progression and computing drug dosage, renal biomarkers find extensive applications in hospitals and diagnostic laboratories across the globe.

Key Points: 
  • As they also aid in predicting disease progression and computing drug dosage, renal biomarkers find extensive applications in hospitals and diagnostic laboratories across the globe.
  • How has the global renal biomarkers market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global renal biomarkers market?
  • What is the structure of the global renal biomarkers market and who are the key players?

Global Clinical Trial Management System (CTMS) Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 18, 2022

The "Global Clinical Trial Management System (CTMS) Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Clinical Trial Management System (CTMS) Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Clinical Trial Management System (CTMS) is a software system used by biotechnology and pharmaceutical industries to handle clinical trials in clinical research.
  • Furthermore, increasing innovative technology developments to reduce the rising cost of clinical trials have resulted in the development of the clinical trial management system.
  • Thus, the increasing number of clinical research studies will boost the use of clinical trial management system solutions, therefore increasing market value.